⚖ Oral Arguments, with Context

The D.C. Circuit hears an appeal by Prescript Pharmaceuticals over the dismissal of its lawsuit against the federal government. Prescript is a California company that buys finished drugs, repackages them, and resells them. The Drug Enforcement Administration says it ordered certain controlled drugs without the required purchasing quotas; Prescript disputes that those rules applied to its repackaging business. In November 2023, the agency immediately suspended Prescript’s registration, citing imminent danger to public health or safety, and agents seized drugs from the company. Prescript sued to challenge that emergency action and seek its property back. While that lawsuit was pending, the agency issued a final decision revoking the registration. The district court then dismissed the suit, reasoning that review now belonged exclusively in a federal appeals court. Prescript will argue that the emergency suspension and seized property still require their own court review; the government will defend dismissal, pointing to the final agency order. A separate proceeding challenges that final revocation itself; this argument concerns whether the district-court lawsuit can continue.

Prescript Pharmaceuticals, Inc. and William Hartig, in his capacity as President of Prescript Pharmaceuticals, Inc., Appellants v. United States Department of Justice, et al. (No. 25-5189) — U.S. Court of Appeals for the D.C. Circuit, argued November 9, 2026.